Oxford BioTherapeutics’ Collaboration With ImmunoGen, Inc.

In UK Gowling WLG, advised on the matter.

Gowling WLG advised Oxford BioTherapeutics with a team including Patrick Duxbury (Picture – Life Science & Health Care).

Oxford BioTherapeutics on a multi-year collaboration with ImmunoGen, Inc. to advance the development of antibody-drug conjugates (ADCs) for the treatment of cancer.

The collaboration will see Oxford BioTherapeutics (OBT) research and develop novel ADCs with ImmunoGen, a leader in the field of ADCs for cancer treatments. Under the agreement, the companies will use ImmunoGen’s linker-payload technology directed to novel targets identified via OBT’s proprietary OGAP® discovery platform. The companies will support the collaboration through joint funding and with OBT receiving an upfront payment from ImmunoGen. Each party will be eligible to receive milestone payments and tiered royalties in respect of each programme selected by the other party for further development.

Oxford BioTherapeutics is a clinical stage oncology company based in Oxford in the UK, San José in California and Morristown in New Jersey USA. It has a pipeline of clinical and pre-clinical immuno-oncology ADC-based therapies and works with key innovators in oncology such as Boehringer Ingelheim and Kite, a Gilead company.

Gowling WLG’s head of life sciences in the UK, Patrick Duxbury (Picture), led on the deal together with legal director Mathilda Davidson. They worked closely with Lindsey Hudson, director of BD and alliance management at OBT.

 

Involved fees earner: Mathilda Davidson – Gowling WLG; Patrick Duxbury – Gowling WLG;

Law Firms: Gowling WLG;

Clients: Oxford BioTherapeutics;

Author: Giulia Di Palma